A Phase 1/1b Open-Label, Dose-Escalation Study of Monoclonal Antibody AV-203 Administered as Monotherapy in Subjects with Metastatic or Advanced Solid Tumors or in Combination with Cetuximab (Erbitux) in Subjects with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Phase of Trial: Phase I
Latest Information Update: 11 Apr 2015
At a glance
- Drugs AV 203 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors AVEO Oncology
- 07 Apr 2015 Status changed from active, no longer recruiting to completed, according to to ClinicalTrials.gov record.
- 02 Jul 2014 New source identified and integrated (M.D. Anderson Cancer Center record:2012-0268)
- 03 Jun 2014 Results presented at the 50th Annual Meeting of the American Society of Clinical Oncology.